INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO

Core Viewpoint - NeoGenomics, Inc. is facing scrutiny due to potential securities fraud or unlawful business practices, as indicated by an investigation initiated by Pomerantz LLP on behalf of investors [1] Financial Performance - For Q2 2025, NeoGenomics reported revenue of $181.3 million, which was below consensus estimates [2] - The company recorded a net loss of $45.1 million for the same quarter [2] - NeoGenomics has revised its 2025 revenue forecast to a range of $720 million to $726 million, down from a previous estimate of approximately $753 million [2] - The adjusted EBITDA projection was also lowered to a range of $41 million to $44 million from a prior range of $55 million to $58 million [2] Market Reaction - Following the announcement of its financial results, NeoGenomics' stock price decreased by $1.21 per share, or 18.73%, closing at $5.25 per share on July 29, 2025 [3]